In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.

Topics covered include:

• Evoke and evoke+ phase III trials of semaglutide
• Subcutaneous lecanemab as initiation and maintenance treatment
• Blood-based biomarker assays
• Trontinemab and other brain shuttles
• Tau targeting therapies in development
• Preventive impact of BCG and herpes zoster vaccination

This podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk. 

Faculty:

Anton P. Porsteinsson, MD 
William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York

Vijay K. Ramanan, MD, PhD
Consultant and Associate Professor
Director, Alzheimer’s Disease Treatment Clinic
Department of Neurology
Mayo Clinic
Rochester, Minnesota 

Link to obtain CME/CE credit: 
https://bit.ly/4999otE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.